These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 24055428

  • 21. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A, Abdullah SE, Niegisch G, Rosenberg JE, Bajorin DF, Grivas P, Apolo AB, Dreicer R, Hahn NM, Galsky MD, Necchi A, Srinivas S, Powles T, Choueiri TK, Pond GR.
    J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
    [Abstract] [Full Text] [Related]

  • 22. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G.
    Cancer; 2000 Apr 01; 88(7):1671-8. PubMed ID: 10738226
    [Abstract] [Full Text] [Related]

  • 23. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.
    Clin Genitourin Cancer; 2011 Sep 01; 9(1):27-30. PubMed ID: 21700509
    [Abstract] [Full Text] [Related]

  • 24. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 25. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G.
    Clin Genitourin Cancer; 2013 Dec 15; 11(4):495-500. PubMed ID: 23800847
    [Abstract] [Full Text] [Related]

  • 26. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 27. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.
    Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, Lord S, Friedlander M, Boyle F, Simes RJ.
    Breast Cancer Res Treat; 2011 Sep 15; 129(2):467-76. PubMed ID: 21445568
    [Abstract] [Full Text] [Related]

  • 28. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF.
    Urology; 2007 Feb 15; 69(2):255-9. PubMed ID: 17320659
    [Abstract] [Full Text] [Related]

  • 29. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M.
    Clin Cancer Res; 2010 Jan 01; 16(1):203-11. PubMed ID: 20008841
    [Abstract] [Full Text] [Related]

  • 30. [PPA (cis-platinum), peplomycin and adriamycin) combination chemotherapy in transitional cell carcinoma of the urothelial tract--pilot study].
    Ono Y, Ohshima S, Fujita T, Naide Y, Suzuki K, Asoh Y, Fukushima M, Ohta K.
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb 20; 21(1):28-33. PubMed ID: 2422307
    [No Abstract] [Full Text] [Related]

  • 31. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
    Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J.
    Clin Genitourin Cancer; 2015 Apr 20; 13(2):185-92. PubMed ID: 25458370
    [Abstract] [Full Text] [Related]

  • 32. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 33. Systemic therapy for metastatic urothelial carcinoma.
    Lin CC, Hsu CH, Pu YS, Vogelzang NJ.
    BJU Int; 2008 Apr 15; 101(7):795-803. PubMed ID: 18070193
    [No Abstract] [Full Text] [Related]

  • 34. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.
    Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG.
    J Clin Oncol; 1999 Oct 15; 17(10):3173-81. PubMed ID: 10506615
    [Abstract] [Full Text] [Related]

  • 35. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
    Koufopoulou M, Miranda PAP, Kazmierska P, Deshpande S, Gaitonde P.
    Cancer Treat Rev; 2020 Sep 15; 89():102072. PubMed ID: 32769039
    [Abstract] [Full Text] [Related]

  • 36. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.
    Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, Fukuhara H, Nishimatsu H, Ishikawa A, Kume H, Homma Y.
    Jpn J Clin Oncol; 2013 Sep 15; 43(9):923-8. PubMed ID: 23888082
    [Abstract] [Full Text] [Related]

  • 37. Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design.
    Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, Nicolai N, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Mariani L, Salvioni R.
    Clin Genitourin Cancer; 2015 Feb 15; 13(1):80-86.e1. PubMed ID: 25027186
    [Abstract] [Full Text] [Related]

  • 38. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
    Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH, Park SR.
    Gastric Cancer; 2018 May 15; 21(3):453-463. PubMed ID: 28828688
    [Abstract] [Full Text] [Related]

  • 39. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Droller MJ.
    J Urol; 2000 May 15; 163(5):1601. PubMed ID: 10798920
    [No Abstract] [Full Text] [Related]

  • 40. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu KI, Fujii Y, Koga F.
    Urol Oncol; 2018 Apr 15; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.